Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vistin Pharma ASA ( (DE:VP4) ) just unveiled an update.
Vistin Pharma ASA has announced that it will publish its fourth-quarter and preliminary 2025 financial results on 12 February 2025 and will host an English-language conference call the same day at 08:30 CET, including a Q&A session for shareholders and other interested parties. The results release and accompanying webcast and telephone conference signal the company’s continued efforts to maintain transparency with investors and stakeholders and provide insight into its operational and financial performance in the competitive European market for Metformin APIs.
More about Vistin Pharma ASA
Vistin Pharma ASA is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride active pharmaceutical ingredient (API), including direct compressible lubricated granules. As a dedicated European Metformin producer, it supplies leading pharmaceutical companies from its manufacturing facility in Kragerø, with headquarters in Oslo and a workforce of highly qualified employees.
Average Trading Volume: 19,844
Current Market Cap: NOK917.9M
Learn more about VP4 stock on TipRanks’ Stock Analysis page.